Global Heparin sodium salt market was valued at 1723 Million US$ in 2018 and is projected to reach 2082 Million US$ by 2024
Wednesday, 17 Jun, 2020
Heparin sodium salt is the sodium salt of sulfated glycosaminoglycans present as a mixture of heterogeneous molecules varying in molecular weights that retains a combination of activities against different factors of the blood clotting cascade. It is present in mammalian tissues and is usually obtained from the intestinal mucosa or other suitable tissues of domestic mammals used for food by man.
Global Heparin sodium salt market was valued at 1723 Million US$ in 2018 and is projected to reach 2082 Million US$ by 2024, at a CAGR of 3.21% during the forecast period.
Heparin is the rapid development of the domestic market in China, in the heparin sodium downstream preparation and quality production enterprises have flashed the dazzle eye.
According to Bayer HealthCare, venous blood clots are responsible for more deaths in Europe every year compared to deaths caused due to breast cancer, prostate cancer, and HIV/AIDS collectively. Additionally, the overall inpatient cost in Europe following VTE is approximately USD 1,968 (EUR 1,804) after three months and USD 3,512 (EUR 3,220) after 12 months. Therefore, frequent/on-time prophylaxis of this condition is essential to reduce the overall cost of treatment. Apart from application in VTE, low molecular weight heparin plays a major role during and after surgical procedures as a measure to prevent formation of blood clots. Unfractionated heparin is the most primitive form which is majorly consumed in hospital setting. The prime applicability of unfractionated heparin is during dialysis. However, the market is steadily shifting towards heparin free dialysis procedures. Although heparin free dialysis is not a new concept in the market, yet it diminishes the chances of bleeding disorders which occurs due to prolonged use of unfractionated heparin. The advent of ultra-low molecular weight heparin (ULMWHs) is relatively new as compared to LMWHs and unfractionated heparin. ULMWHs are structurally similar to low molecular weight heparin yet their monosaccharide/oligosaccharide compositions and average molecular weights differ considerably due the variable anticoagulant activities. Majority of the research studies in Europe are now focused on ultra-low molecular weight heparin as a comparative study with LMWHs for treatment of neurological disorders and cancer associated coagulation ailments. Success of these clinical trials is expected to augment the market in coming years.
Key players in global Heparin sodium salt market include: Sanofi-Aventis, Pfizer, Hepalink, SPL
SANDOZ, LEO Pharma, Organon Pharmaceutical, Opocrin, Bioibérica, King-friend, Dongcheng Biochemicals, Changzhou Qianhong, Hebei Changshan Biochemical etc.